Charles Frost

TL;DR: Apixaban is an orally bioavailable inhibitor of factor Xa with elimination pathways that include metabolism and renal excretion with no serious adverse events or discontinuations due to adverse effects.

TL;DR: The suitability of commercially available prothrombin time/international normalised ratio (PT/INR) and anti-FXa activity assays to measure FXa inhibitors in plasma was evaluated and suggested that anti-Xa activity was the better indicator of apixaban plasma concentrations.

TL;DR: To evaluate apixaban single dose safety, tolerability, pharmacokinetics and pharmacodynamics and assess the effect of food on Apixaban pharmacokinetically, a large number of animals were tested.

TL;DR: Multiple oral doses of apixaban were safe and well tolerated over a 10-fold dose range, with pharmacokinetics with low variability and concentration-related increases in clotting time measures.

TL;DR: The modest change inApixaban exposure is unlikely to require dose adjustment for apixaban based on body weight alone, however, caution is warranted in the presence of additional factors (such as severe renal impairment) that could increase apixaba exposure.